SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following its Q4 earnings report, where an EPS and revenue beat was overshadowed by cautious subscriber growth guidance and financial implications of the Warner Bros. Discovery acquisition, including a pause in share buybacks. This has ignited a fierce debate among investors, with many seeing the significant price drop as a generational 'buy the dip' opportunity for long-term content expansion, while others voice strong concerns about the deal's debt, halted buybacks, and Netflix's slowing growth in a competitive streaming market.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is trending after announcing an AI licensing partnership in Africa, which has ignited intense community discussion about its market potential. Many traders are focused on the stock's low float and high reported borrow fees, speculating on a significant short squeeze, while others express caution regarding its volatility.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to reports of exceptionally high-grade silver drill results across its vast land, significantly boosting optimism for future production. The community is actively discussing continuous insider buying by Eric Sprott and surging precious metal prices as catalysts for substantial upside, while also considering the company's non-producing status and potential for dilution. This confluence of factors, coupled with discussions of a possible short squeeze and growing silver demand, is driving intense conversation around the mining company.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is surging as the community keenly anticipates an imminent PMDA approval in Japan, following groundbreaking pancreatic cancer trial results demonstrating an 81% disease control rate. This pivotal regulatory decision, coupled with FDA module submission and growing institutional interest, underscores the revolutionary potential of their Alpha DaRT technology in oncology, driving widespread bullish sentiment.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing an "insane" rally to new all-time highs, fueled by escalating geopolitical tensions, particularly President Trump's tariff threats against Europe concerning Greenland, alongside broader concerns about US debt and dollar debasement. The community is sharply divided, with bulls celebrating significant gains and predicting much higher prices, while bears warn of a "bubble" and anticipate a "violent pullback" once tensions de-escalate. This robust surge highlights gold's role as a primary safe-haven asset amidst global uncertainty and questions surrounding fiat currency stability.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is trending amid conflicting analyst assessments, with recent downgrades from Bank of America and Goldman Sachs over valuation and SoftBank's large stake sparking community debate about motives. Despite this selling pressure, discussion highlights ARM's foundational role in AI, data centers, and its new 'Physical AI' robotics division, with many viewing current price action as an accumulation opportunity given its critical position in future tech.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending as recent significant contract wins with the U.S. Department of Health and Human Services and the U.S. Army are fueling investor optimism. The community is actively discussing how these federal deals, alongside the new CEO's deep government background, could signal a turnaround for the enterprise AI software provider. Furthermore, high short interest is prompting talk of a potential squeeze if this positive momentum continues.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid intense market focus on an upcoming high-profile address and recent geopolitical rhetoric, particularly concerning Greenland and global trade. The community is sharply divided, with many anticipating a quick market rebound while others brace for further downside, linking market direction to these unfolding events. This dynamic fuels significant volatility as participants actively debate the broader implications for the economy.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as President Trump's aggressive rhetoric regarding Greenland and potential new tariffs, coupled with concerns over Japan's bond market, fuels a broad market sell-off. The community is sharply divided, with many anticipating further declines and a retest of crucial support levels, while others expect an eventual 'buy the dip' recovery, viewing current fears as an overreaction.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending as a major institutional holder has registered its substantial stake for a potential sale, creating significant market buzz. This move has ignited a sharp debate among investors, with some viewing it as a bearish signal after a period of underperformance, while others see an attractive opportunity in this dividend-yielding consumer staple. The broader context includes anticipation of a planned company separation into distinct entities, which many believe could unlock value despite ongoing competitive pressures in the food sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of "Moderate Buy" by Brokerages

Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, MarketBeat.com reports...

Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1%

Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 503,479...

Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy

Chardan Capital raised Kalaris Therapeutics to a "strong-buy" rating in a research note on Tuesday...

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are presently covering the firm, MarketBeat.com...

Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Monday Sector Laggards: Biotechnology, Electronic Equipment & Products

In trading on Monday, biotechnology shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of Quince Therapeutics, down about 16.2% and shares of Kalaris...

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five research firms that are covering the company, Marketbeat.com...

Leerink Partnrs Issues Pessimistic Outlook for KLRS Earnings

Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) - Research analysts at Leerink Partnrs dropped their Q4 2025 EPS estimates for Kalaris Therapeutics in a report issued on Monday, November 17th...

What is William Blair's Estimate for KLRS FY2025 Earnings?

Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) - Research analysts at William Blair decreased their FY2025 earnings per share estimates for shares of Kalaris Therapeutics in a research note...

Kalaris Therapeutics (NASDAQ:KLRS) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of...

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company is headquartered in Berkeley Heights, NJ.

Kalaris Therapeutics Inc.

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$9.81
Prev Close	$9.74
Open	$9.56
Dividend Yield	0.00%
50-Day Moving Average	$7.56
Beta	0.94
Avg. Volume	180,486.82
PE Ratio	-1.33

52-Week High	$12.90
52-Week Low	$2.14
Market Capitalization	$182.16M
EPS (Annual)	-$11.73
Price to Book	4.38
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

KLRS
Kalaris Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KLRS News

KLRSKalaris Therapeutics